CompletedNCT01567527
Aripiprazole Injection or Placebo to Prevent Mood Episodes in Bipolarity
About this title
Read the official source — NCT01567527Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 75 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateAugust 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 731
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, Japan, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01567527
- Official title
Show the full official title
52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham, United States · Springdale, United States · Beverly Hills, United States
73 more locations
- Costa Mesa, United States
- Escondido, United States
- Garden Grove, United States
- Los Angeles, United States
- National City, United States
- Oceanside, United States
- Orange, United States
- Pico Rivera, United States
- Riverside, United States
- San Diego, United States
- Temecula, United States
- Torrance, United States
- Lauderhill, United States
- Leesburg, United States
- Melbourne, United States
- Oakland Park, United States
- Atlanta, United States
- Decatur, United States
- Smyrna, United States
- Hoffman Estates, United States
- New Orleans, United States
- Rockville, United States
- Flowood, United States
- Saint Charles, United States
- St Louis, United States
- Lincoln, United States
- Cherry Hill, United States
- Brooklyn, United States
- Buffalo, United States
- New York, United States
- Cincinnati, United States
- Dayton, United States
- Oklahoma City, United States
- Allentown, United States
- Jenkintown, United States
- Austin, United States
- Dallas, United States
- Wichita Falls, United States
- Richmond, United States
- Chatham, Canada
- Aizu-Wakamatsu, Japan
- Sapporo, Japan
- Morioka, Japan
- Kawasaki-shi, Japan
- Yokohama, Japan
- Kashihara, Japan
- Sakai, Japan
- Sakai-shi, Japan
- Fukuoka, Japan
- Itabashi-bu, Japan
- Kanzaki-gun, Japan
- Koriyama-shi, Japan
- Kumamoto, Japan
- Okinawa, Japan
- Shinjuku-ku, Japan
- Tokyo, Japan
- Tottori, Japan
- Toyama, Japan
- Gdynia, Poland
- Bydgoszcz, Poland
- Chełmno, Poland
- Choroszcz, Poland
- Targoviste, Romania
- Bucharest, Romania
- Judet Lasi, Romania
- Anyang-si, South Korea
- Goyang-si, South Korea
- Daejeon, South Korea
- Jeju City, South Korea
- Seoul, South Korea
- Keelung, Taiwan
- Taipei, Taiwan
- Taouyuan County, Taiwan
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Intramuscular (IM) Depot Aripiprazole and Intramuscular (IM) Depot Placebo.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
